Disease · EFO_0004272

anemia (phenotype)

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anemia (phenotype). Diseases, record EFO_0004272. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004272

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anemia (phenotype); Open Targets
Open Targets ID: EFO_0004272; Open Targets
Disease Ontology: DOID:2355; Disease Ontology
MeSH: D000740; MeSH
NCI Thesaurus: C2869; NCI Thesaurus
Highest stage of its drugs: Approval, for 54 of its 84 drugs, from ATC and DailyMed; Open Targets

Drugs84

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DARBEPOETIN ALFA	CHEMBL1201566	Protein	Approval	ATC and DailyMed	66	64	59	Drugs and targets
EPOETIN BETA	CHEMBL2109092	Protein	Approval	ATC	33	32	16	Drugs and targets
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	CHEMBL3707314	Protein	Approval	ATC and DailyMed	26	24	24	Drugs and targets
VADADUSTAT	CHEMBL3646221	Small molecule	Approval	ATC	17	16	15	Drugs and targets
PEGINESATIDE	CHEMBL2107866	Protein	Approval	ATC	15	14	14	Drugs and targets
FERROUS SULFATE	CHEMBL1200830	Small molecule	Approval	ATC	13	12	6	Drugs and targets
IRON SUCROSE	CHEMBL1200823	Small molecule	Approval	ATC	13	12	12	Drugs and targets
ROXADUSTAT	CHEMBL2338329	Small molecule	Approval	ATC	13	12	12	Drugs and targets
MOLIDUSTAT	CHEMBL3646118	Small molecule	Approval	ATC	6	4	3	Drugs and targets
LUSPATERCEPT	CHEMBL3039545	Protein	Approval	ATC	5	4	4	Drugs and targets

1 to 10 of 84

See all 84 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EPOR	Erythropoietin receptor	6	Erythropoietin receptor agonist	Approval	https://conductscience.org/library/genes/2057	Drugs and targets
EGLN1	Egl nine homolog 1	4	Egl nine homolog 1 inhibitor; Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/54583	Drugs and targets
EGLN2	Hypoxia-inducible factor prolyl hydroxylase	4	Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor; Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/112398	Drugs and targets
EGLN3	Hypoxia-inducible factor prolyl hydroxylase	4	Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/112399	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/1642	Drugs and targets
P4HTM	Hypoxia-inducible factor prolyl hydroxylase	2	Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/54681	Drugs and targets
RBX1	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 3	https://conductscience.org/library/genes/9978	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor agonist	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials235

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02892149	Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)	Phase 3	3,554	2022-06-28	Anemia, Dialysis-Dependent Chronic Kidney Disease	DARBEPOETIN ALFA, VADADUSTAT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02174627	Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis	Phase 3	2,781	2019-12-16	Anemia	ROXADUSTAT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00358215	RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial	Phase 3	2,278	2013-12-13	Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure	DARBEPOETIN ALFA	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02174731	Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.	Phase 3	2,133	2019-12-16	Anemia	EPOETIN ALFA, ROXADUSTAT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02648347	Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease	Phase 3	1,751	2022-06-27	Anemia, Non-Dialysis-Dependent Chronic Kidney Disease	DARBEPOETIN ALFA, VADADUSTAT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02680574	Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Phase 3	1,725	2022-06-27	Anemia, Non-Dialysis-Dependent Chronic Kidney Disease	DARBEPOETIN ALFA, VADADUSTAT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02278341	Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis	Phase 3	838	2020-08-26	Anemia, End Stage Renal Disease (ESRD)	DARBEPOETIN ALFA, EPOETIN ALFA, ROXADUSTAT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00597584	Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis	Phase 3	823	2012-07-30	Chronic Renal Failure, Chronic Kidney Disease, Anemia	EPOETIN ALFA, EPOETIN BETA, PEGINESATIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00597753	Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis	Phase 3	803	2012-07-30	Chronic Renal Failure, Chronic Kidney Disease, Anemia	EPOETIN ALFA, PEGINESATIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00077610	A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients	Phase 3	673	2016-02-29	Anemia	EPOETIN ALFA, EPOETIN BETA, METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov

1 to 10 of 235

See all 235 trials

Comparisons in its trials122

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vadadustat vs Darbepoetin Alfa: deaths from any cause	276 of 1,768	290 of 1,769	3,537	NCT02892149	Trial comparisons
Vadadustat vs Darbepoetin Alfa: serious adverse events	973 of 1,768	1,032 of 1,769	3,537	NCT02892149	Trial comparisons
Roxadustat vs Placebo: deaths from any cause	284 of 1,384	245 of 1,377	2,761	NCT02174627	Trial comparisons
Roxadustat vs Placebo: serious adverse events	795 of 1,384	749 of 1,377	2,761	NCT02174627	Trial comparisons
Darbepoetin Alfa vs Placebo: serious adverse events	781 of 1,133	741 of 1,140	2,273	NCT00358215	Trial comparisons
Roxadustat vs Epoetin Alfa: deaths from any cause	247 of 1,048	231 of 1,053	2,101	NCT02174731	Trial comparisons
Roxadustat vs Epoetin Alfa: serious adverse events	604 of 1,048	606 of 1,053	2,101	NCT02174731	Trial comparisons
Vadadustat vs Darbepoetin Alfa: deaths from any cause	180 of 878	168 of 870	1,748	NCT02648347	Trial comparisons
Vadadustat vs Darbepoetin Alfa: serious adverse events	573 of 878	561 of 870	1,748	NCT02648347	Trial comparisons
Vadadustat vs Darbepoetin Alfa: deaths from any cause	139 of 861	139 of 862	1,723	NCT02680574	Trial comparisons

1 to 10 of 122

See all 122 comparisons in its trials

Papers from its trials111

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33883252	RESULT	1	PubMed
33650630	RESULT	1	PubMed
27354480	RESULT	1	PubMed
26370220	RESULT	1	PubMed
23343062	RESULT	4	PubMed
23343061	RESULT	4	PubMed
22874106	RESULT	2	PubMed
22081263	RESULT	1	PubMed
20973982	RESULT	1	PubMed
20929915	RESULT	1	PubMed

1 to 10 of 111

See all 111 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0004272

GET https://conductscience.org/api/diseases/v1/EFO_0004272/drugs?page=2

API reference For AI assistants